Orphan Drug Designation Granted to Adze-1.17-CD40L for the treatment of Malignant Glioma
“This important designation is a milestone in the development of our Adze-1.17 oncolytic immunotherapy platform and highlights the need for potential new treatment options for patients with Malignant Gliomas and other difficult to treat cancers,” said Sidney Hopps, Chief Executive Officer of Adze Biotechnology. “The novel Adze-1.17 oncolytic immunotherapy platform is designed for both systemic and intra-tumoral delivery of immunotherapy payload combinations to various types of solid tumors. We look forward to advancing this therapy into the clinic.”
Share:
More News
“From the outset, our goal has been to build a discovery engine that systematically unlocks high-value, challenging targets and delivers first-in-class precision medicines,” said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares. “This collaboration lets us scale that engine alongside Novartis’ world-class development capabilities and global reach, so we
“We are very pleased that the iDMC has recommended continuation of the landmark OVATION 3 clinical trial without modification, representing another important validation of the remarkable efficacy and safety data previously reported and further indicating the potential for IMNN-001 to represent a historic advance in the treatment of ovarian cancer,”
“VS-7375 has demonstrated anti-tumor activity across multiple dose levels and tumor types, encouraging signals from rational combination strategies, and a favorable safety profile that improves meaningfully beyond the first treatment cycle, underscoring its potential to be not only the best-in-class oral KRAS G12D inhibitor, but also the preferred treatment option
“We are pleased that the FDA has demonstrated urgency in reconsidering the RP1 BLA with an expeditious action date in recognition of the significant unmet need for advanced melanoma patients and support from the broader melanoma community,” said Sushil Patel, Ph.D., CEO of Replimune. “We look forward to a productive